Thursday - May 1, 2025
LANSING, Mich., Feb. 18, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today the National Labor Relations Board (NLRB) has withdrawn its unfair labor practices claim against the Company. The claim was withdrawn following a mutual agreement, with no admission of wrongdoing by Neogen.
In the coming weeks, Lansing warehouse shipping clerks and material handling employees will have the opportunity to vote in an election to determine whether they wish to unionize.
"At Neogen, we are dedicated to fostering a supportive and equitable workplace where employees feel valued and heard," said Amy Rocklin, Chief Legal and Compliance Officer. "We respect our employees' rights and we prioritize a positive work environment. Neogen remains committed to supporting our employees throughout this process and will continue to comply fully with all legal obligations related to the election."
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Contact
PR@Neogen.com
Last Trade: | US$5.05 |
Daily Change: | 0.02 0.40 |
Daily Volume: | 6,028,838 |
Market Cap: | US$1.100B |
January 21, 2025 January 10, 2025 December 17, 2024 October 10, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load